09.08.11
Angioslide Ltd., based in Caesarea, Israel, recently announced the first procedures have been conducted using the company's new 5x300mm Proteus device for treating the superficial femoral artery (SFA). Superficial femoral artery provides blood to the arteries that circulate the knee and foot. Like other arteris, the SFA can become blocked. The technology combines a percutaneous transluminal angioplasty (PTA) balloon and embolic capture of particles in one device. The new 5x300 mm size joins Angioslide's current dedicated product line solutions for the lower limbs.
Initial treatments using the new device were conducted at centers in Germany.
According to the company the Proteus 5X300 mm makes it possible to treat lesions up to 300 mm with one device, while providing an immediate solution for embolic capture.
"Angioslide's breakthrough technology, now available also in 300 mm length as well, is a unique solution for lesions with high level of embolic material, including chronic total occlusions (CTO), in stent-restenosis, thrombus containing lesions and post atherectomy PTA," said Prof. Thomas
Zeller, head of the Angiology Department at the Heart Center in Bad-Krozingen. Germany.
Compay execs are betting that with the increase in life expectancy, diabetes prevalence, and number of high-risk patients, together with the shift toward an "endovascular-first" approach as a preferred procedure over surgical revascularization, there is a growing need for expanding the current interventional "tool box" to accommodate procedures designed specifically to treat long and diffuse lesions in a quick and effective manner.
"We are committed to introducing new products to the market continuously, addressing the growing range of endovascular solutions," said Lihu Avitov, Angioslide CEO. "With patients' needs in mind, the 5X300 mm device is the first in a series of long balloons, adding to our current
offering of 20-100 mm devices. The Proteus product family provides additional confidence to clinicians treating their endovascular patients."
The device current is approved in the European market only and is being reviewed by the U.S. Food and Drug Administration. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe.
.
Initial treatments using the new device were conducted at centers in Germany.
According to the company the Proteus 5X300 mm makes it possible to treat lesions up to 300 mm with one device, while providing an immediate solution for embolic capture.
"Angioslide's breakthrough technology, now available also in 300 mm length as well, is a unique solution for lesions with high level of embolic material, including chronic total occlusions (CTO), in stent-restenosis, thrombus containing lesions and post atherectomy PTA," said Prof. Thomas
Zeller, head of the Angiology Department at the Heart Center in Bad-Krozingen. Germany.
Compay execs are betting that with the increase in life expectancy, diabetes prevalence, and number of high-risk patients, together with the shift toward an "endovascular-first" approach as a preferred procedure over surgical revascularization, there is a growing need for expanding the current interventional "tool box" to accommodate procedures designed specifically to treat long and diffuse lesions in a quick and effective manner.
"We are committed to introducing new products to the market continuously, addressing the growing range of endovascular solutions," said Lihu Avitov, Angioslide CEO. "With patients' needs in mind, the 5X300 mm device is the first in a series of long balloons, adding to our current
offering of 20-100 mm devices. The Proteus product family provides additional confidence to clinicians treating their endovascular patients."
The device current is approved in the European market only and is being reviewed by the U.S. Food and Drug Administration. The device has also received European CE Mark approval for lower limb use and is being marketed in selected regions in Europe.
.